BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT ...

Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ...

The cuts impact more than $2.4 billion in grant money, including $1.3 billion in grant funds already spent on projects ...

Tesla CEO Elon Musk is expected to step down from his position helming the federal Department of Government Efficiency (DOGE) ...

While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses ...

FDA Chief Medical Officer Hilary Marston, M.D., is leaving her position at the agency.  | The FDA’s Chief Medical Officer ...

British biotech CellCentric is settling into a new office in Boston, part of the company’s expansion into the U.S. as ...

Medtronic has inked a neurovascular partnership with Methinks AI, a Barcelona, Spain-based developer of programs to detect ...

Following the FDA clearance of its Versius robot last fall, CMR Surgical has posted another major funding round, raising more ...

“As part of Cyclacel’s efforts to reduce operating costs, it has determined to focus on the development of plogosertib, a polo-like kinase 1 inhibitor for treatment of advanced cancers and ...

The Trump administration is halting research funding to Princeton University and reviewing about $9 billion in federal grants and contracts to Harvard University, the latest escalation of the ...

Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 ...